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Abstract
Purpose Minimally invasive surgical ablation for atrial
fibrillation(AF)hasshowngoodresultsandlowcomplications
incidence. Our objective was to evaluate feasibility and
efficacy of this technique in our center.
Methods The procedure included pulmonary vein isolation,
ganglionic plexi ablation, ligament of Marshall resection, and
left atrial appendage exclusion through beating heart mini-
mally invasive bilateral thoracotomies. Patients were moni-
tored daily by telemedicine during the first 4 months and then
by quarterly24-hHoltermonitoring orbyimplantable cardiac
monitor. Ablation success was defined as freedom from any
atrial tachyarrhythmia recurrence lasting more than 30 s and
fromantiarrhythmicdrugs.Allpatientswerefollowedupfora
minimum of 12 months.
Results Twenty-two consecutive patients with AF, paroxys-
mal in 27% and persistent in 73%, were treated. Mean age
was 63±10 years, 86% were men. Seventy-three percent of
patients had previously undergone to one or more catheter
ablations. Median follow-up period was 22 months (25°–75°
percentile, 20–27). Patients free from any arrhythmia
recurrence for at least 6 consecutive months discontinued
antiarrhythmic therapy. Ablation was successful in 73% of
patients at 12 months. Freedom from AF recurrences
independently from antiarrhythmic therapy status was 91%
at 12months. Results wereconsistent in patients that reached
24 months follow-up. There were no deaths. Complications
were: one conversion to sternotomy owing to thoracic
adherences, one pacemaker implant, and one postoperative
hemothorax requiring surgical revision.
Conclusions Our results show that minimally invasive
surgical ablation was feasible and gave satisfactory results at
long-term term follow-up in patients with AF.
Keywords Minimally invasive stand-alone surgical
ablation.Atrial fibrillation.Pulmonary vein isolation
1 Introduction
Atrial fibrillation is the most common sustained cardiac
arrhythmia, affecting around 1% of the global population
[1]. Symptoms are caused by a poorly controlled or irregular
ventricular rate, and the associated risk of death is doubled in
patients with a history of atrial fibrillation [2]. In recent
years, transvenous pulmonary vein isolation has become the
first choice for patients with highly symptomatic atrial
fibrillation refractory to antiarrhythmic drugs [3]. The
reported percentage of success of this procedure varies from
45% to 85% according to patients' characteristics, adopted
technique, and ECG monitoring method used during follow-
up [4–6]. Transvenous pulmonary vein isolation is not
exempt from major complications and, in one third of
patients, more than one procedure is necessary [7].
More recently, various techniques of minimally invasive
surgical pulmonary vein isolation have been developed,
which have yielded success rates of 50–100%, depending
on primary endpoint definition and ECG monitoring
method, with an incidence of major complications inferior
to 5% [8–14]. The European Society of Cardiology
suggests considering stand-alone surgical ablation in
patients with symptomatic atrial fibrillation refractory to
antiarrhythmic drugs that prefer a surgical approach, have
undergone one or more failed attempts at catheter ablation,
or are not candidates for catheter ablation [15]. We describe
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2 Methods
2.1 Patient population
From June 2008 to May 2010, 22 patients (86% male, mean
age 60±11) underwent stand-alone surgical ablation of
atrial fibrillation in our center. These patients had highly
symptomatic idiopathic atrial fibrillation refractory to at
least two antiarrhythmic drugs: paroxysmal in 6 (23%) and
persistent in 16 (73%) according to the definitions of the
ESC 2010 Guidelines [16]. The mean ejection fraction in
our population was 61±12%. Idiopathic dilated cardiomy-
opathy was present in only one patient with depressed
ejection fraction (<35%) and a previously implanted ICD.
Sixteen patients (73%) were affected by hypertension but
with no structural cardiac involvement. CHADS2 score was
1 for all the patients except for one that had a previous
transient ischemic attack. Fifteen patients (68%) had
previously undergone a mean of 2.6±2.8 electrical cardio-
versions, 6 (27%) at least one pharmacological cardiover-
sion, and 16 (73%) a mean of 1.6±1.1 catheter pulmonary
vein ablations. Six patients, two with paroxysmal and four
with persistent atrial fibrillation, opted for minimally
invasive surgical ablation as first procedure, without
undergoing previous catheter ablation. Table 1 summarizes
the baseline characteristics of the patients.
2.2 Surgical procedure
The procedure includes pulmonary vein isolation, ganglionic
plexi ablation, ligament of Marshall resection, and left atrial
appendage exclusion by means of beating heart minimally
invasive bilateral thoracotomies. Oral anticoagulation is
discontinued 3 days before the procedure and replaced by
heparin that is suspended 12 h before surgery. All the patients
undergo to transesophageal echocardiography before the
procedure.
Patients receive general anesthesia and are intubated
with a double-lumen tube (Carlens). The operation starts at
the right side of the chest. On the operating table, the
patient is placed in the classic lateral position on the left
side and a 5–6.0-cm incision is made in the third or fourth
right intercostal space; a small incision is also made on the
midaxillary line in the sixth intercostal space for the camera
port (Fig. 1). The subcutaneous tissue and the intercostal
musculature are dissected while maintaining the anatomical
integrity of the intercostal muscles, in order to avoid
bleeding and hematomas, and a soft tissue retractor and a
small rib spreader are inserted.
Under thoracoscopy, the phrenic nerve is identified and the
pericardium is opened 2 cm in front of the nerve, the superior
vena cava, and inferior vena cava to display the heart (Fig. 1).
Stay sutures are then placed for better exposure of
pulmonary veins and to facilitate dissection in transverse
and oblique sinus. Blunt dissection is performed on the upper
part of the pulmonary veins and also in oblique sinus in front
of inferior vena cava. Pulmonary veins are completely
encircled by means of a special dissector (Navigator;
Table 1 Baseline characteristics of the patients
N=22
Age (years) 63±10
Male, n (%) 19 (86)
Atrial fibrillation type
Paroxysmal, n (%) 6 (27)
Persistent, n (%) 16 (73)
LAD (mm) 47±5
LVEF (%) 61±12
Hypertension 16 (73%)
Diabetes 1 (5%)
Idiopathic dilated cardiopathy 1 (5%)
Previous ICD implanted 1 (5%)
Previous TIA/stroke 1 (5%)
Oral anticoagulation 20 (91%)
Amiodarone 13 (59%)
Flecainide or propafenone 13 (59%)
Sotalol 4 (18%)
Ca-antagonist 2 (9%)
ICD implantable cardiac defibrillator, LAD left atrial diameter, LVEF
left ventricular ejection fraction, TIA transient ischemic attack
Fig. 1 Surgical procedure. A 5–6.0-cm incision is made in the third or
fourth right intercostal space; a small incision is also made on the
midaxillary line in the sixth intercostal space for the camera port. The
pericardium is opened 1–2 cm anterior to the phrenic nerve (this figure
has been kindly provided by Medtronic Inc.)
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pulmonary veins.
To identify predominantly vagal ganglionic plexi, high-
frequency electrical stimulation (800 pulses per minute,
pulse width 9.9 ms) was applied at 10 sites on the epicardial
fat pads of the left atrium and pulmonary veins according to
a map adapted from Warren Jackman, University of
Oklahoma [10], by using an electrosurgical irrigated,
monopolar, radiofrequency ablation device (MAPS,
Medtronic Inc.). MAPS device is able to map, ablate, pace,
and sense in bipolar mode. When stimulated, a transient AV
block is induced due to vagal response and the correlating
autonomic ganglia are identified. Positive response was
defined as ≥50% increase in mean R–R interval [10]. The
regions with autonomic ganglia, and also the whole of the
para-atrial fat tissue, are then ablated by means of irrigated
radiofrequency energy, which is delivered by the same
device. Ablation is carried out at a power of 20–25 W. The
endpoint for autonomic ganglia ablation is the nonreprodu-
cibility of the transient AV block.
The bipolar radiofrequency clamp (Gemini-S, Medtronic
Inc.) is then inserted, and two transmural lines are created
around the pulmonary veins: one in the direction of the
right lung and the other in the direction of the right atrium.
The radiofrequency generator emits an acoustic and a visual
signal when transmurality is achieved. In order to test the
electrical isolation of the pulmonary veins, sensing and
pacing no less than 1 cm away from the visible lesion are
carried out by the MAPS device. The endpoint for
pulmonary vein ablation is their complete electrical
isolation in terms of entrance and exit block into and from
them. Entrance block assessment is accomplished by
monitoring atrial EGM potentials pre- and postablation on
both sides of the lesion for comparison to each other and to
those measured previously. Conduction block is demon-
strated by absence or reduced potentials in the area isolated
by the ablation lesion when compared to left atrial activity
outside that area. In patients in sinus rhythm during the
procedure, a pacing of the isolated area is performed to verify
the presence of conduction block; in patients in atrial
fibrillation during the procedure, the sensing is performed
inside the isolated area to verify the presence of a significant
dropinits electricalactivitywhencomparedtoothers(Fig. 2).
The ablation is repeated until the complete electrical isolation
is demonstrated.
The right side procedure is completed by inserting a chest
tube (16-Fr Blake drain) through the incision of the camera
port. The wound is closed in the standard manner with one or
two strong prolene pericostal sutures, and subcutaneous and
intracutaneous skin sutures.
The patient is then turned into the right lateral position
and exactly the same procedure is repeated, the only
difference being that the pericardium is opened 2 cm below
the phrenic nerve and the Marshall ligament is separated by
means of sharp dissection and ablated with the MAPS
device. Autonomic ganglia are then mapped and ablated as
described above. The bipolar radiofrequency clamp is led
around the left pulmonary veins with the greater curve of
Pre-ablation
Post-ablation
(A)
Sensing near PV
(area to be
isolated) 
(C)
Sensing inside
the isolated area 
(B)
Sensing on
atrium (area not
to be isolated) 
(D)
Sensing on
atrium outside
the isolated area 
Fig. 2 Example of pre- and post-
ablation sensing performed in
patient in atrial fibrillation during
the procedure to verify the
conduction block. The EGM
traces inside and outside the
isolated area are compared before
and after the ablation. Trace from
inside isolated area postablation
(c) can be either silent or in its
own rhythm if the ectopic foci
happen to be firing. In either case,
this should look very different
from the trace taken from same
area preablation (a) and from
outside the isolated area pre-
and postablation (b and d,
respectively) due to the
decreased potentials
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the atrial cuff of the connection of the pulmonary veins to
the left atrium, and two ablation lines are created at a
distance of 4–5 mm from each other.
Again, the effectiveness of the block is checked by the
MAPS device. The left atrial appendage is then excluded by
means of a purse-string suture around the base, using a
Teflon pledget-supported 4–0 prolene suture. The left side
procedure is also completed by inserting a drainage tube
and closing the wound. At the end of the procedure,
300 mg of amiodarone is administered intravenously to all
patients and, if the arrhythmia persists, electrical cardio-
version is performed.
2.3 Postoperative and follow-up management
After surgery, the patients were transferred to the
intensive care unit for 24 h observation. Chest X-ray
was performed routinely in the intensive care unit.
Postablation heart monitoring was performed by telem-
etry and 48-h Holter recording. Drainage tubes were
usually removed during the first postoperative day.
Amiodarone was administered intravenously to all
patients during the first day (900 mg/24 h). In the
event of persistent atrial fibrillation recurrence, electrical
cardioversion was performed after sedation. All patients
received the following drug therapy after surgery:
600 mg/day of amiodarone during the first postoperative
week, 400 mg/day of amiodarone during the second
postoperative week, and 200 mg/day of amiodarone
from the third postoperative week onwards. If the
patient was intolerant to amiodarone, 150 mg/day of
flecainide or 450 mg/day of propafenone associated to
80 mg/day of sotalol was prescribed.
If the patient had no any arrhythmia recurrence for at
least 6 consecutive months of follow-up, the antiar-
rhythmic therapy was discontinued. Except for the only
patient with high risk factor (CHADS2 score=3), oral
anticoagulation therapy was prescribed on discharge
only to patients with arrhythmia recurrence during the
hospital stay.
The first 19 treated patients were enrolled in a tele-
medicine program during the first 4 months of follow-up
and were instructed to transmit 3 min of ECG four times
per day and in case of symptoms. The last three treated
patients received an implantable cardiac monitor (Reveal
XT, Medtronic Inc.) on the same day of the surgical
procedure. All the patients performed an ambulatory
examination after 3, 6, 9, and 12 months from the
procedure and then every 6 months. Patients with no
cardiac monitor implanted performed a 24-h Holter after the
end of the telemedicine program at 6, 9, and 12 months and
then every 6 months. Patients were also instructed to come
to the hospital in case of symptoms for extra ECG recording.
At the 6-month follow-up examination, echocardiography
was performed in all patients.
2.4 Study endpoints
Freedom from any atrial arrhythmia recurrence lasting
more than 30 s at 12 months follow-up, off antiarrhyth-
mic drugs and regardless of presence or absence of
symptoms, was deemed to indicate procedure success.
Secondary endpoints considered were freedom from any
atrial arrhythmia recurrence lasting more than 30 s and
freedom from atrial fibrillation recurrence lasting more
than 30 s independently from the antiarrhythmic therapy
status.
2.5 Statistical analysis
Continuous variables were expressed as means and standard
deviations, if normal, and as median and range, if not normal.
Skewness was assessed by means of Shapiro–Wilk test.
Discrete variables were expressed as absolute and relative
frequencies. All analyses were carried out by means of the
SPSS 12.02 statistical package (SPSS Inc, Chicago, IL).
3 Results
3.1 Perioperative results
The surgical procedure, including autonomic ganglia
ablation, ligament of Marshall resection, and left atrial
appendage exclusion, was successfully completed in all
patients. The median length of the surgical procedure was
3.2 h (range 2.1 to 5.5 h) from the time of initial skin
incision to skin closure on the contralateral side. At the
beginning of the procedure, 18 patients (82%) were in atrial
fibrillation. In patients that previously performed catheter
ablation, adherences due to atrial injury were found that
made more difficult to isolate pulmonary vein; anyway, this
was successfully performed in all the patients.
Three patients had operative complications: one conver-
sion to sternotomy due to thoracic adherences, one need for
permanent pacemaker, and one postoperative hemothorax
requiring surgical revision. In three patients, intraoperative
cardioversion was necessary in order to achieve sinus
rhythm. The mean duration of postoperative stay in the
intensive care unit was 2.1±2.2 days. Four patients (18%)
had atrial fibrillation recurrences before discharge and
required electrical cardioversion; in one case, this was
unsuccessful. The mean total hospital stay was 4.3±
2.1 days. At the time of discharge, 21 patients (95%) were
in sinus rhythm.
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The median duration of follow-up was 22 months (25°–75°
percentile, 20–27 months). Ablation success in terms of
freedom from any atrial arrhythmia recurrence (atrial
fibrillation/flutter/tachycardia) lasting more than 30 s and
antiarrhythmic drugs off was reached in 73% of patients at
12 months (Fig. 3). Freedom from any arrhythmia
recurrences independently from antiarrhythmic therapy
status was 77%, while freedom from atrial fibrillation
recurrences only was 91% at 12 months (Fig. 3). These
results were consistent in the 10 patients that reached the
24-month follow-up.
Figure 4 reports the diagram of arrhythmia recurrences and
management. Fourteen patients (64%) never had any atrial
arrhythmia recurrences and could discontinue the antiarrhyth-
mic drug after the 6-month follow-up visit. One patient always
remained in atrial fibrillation, and it was decided to not further
treat him due to his previous transient ischemic attack. Other
three patients had atrial fibrillationrecurrences after an average
time of 3±3 months, while four had new-onset persistent left
atrial flutter episodes after an average time of 8±5 months
following surgical ablation.
Table 2 summarizes the detailed treatments and outcome
of the patients with at least one atrial arrhythmia recurrence.
The four patients (18%) with persistent left atrial flutter
recurrences were indicated to flutter ablation (cavotricuspid
isthmus ablation plus linear lesion between the mitral annulus
and the superior right pulmonary vein): two patients already
performedit;oneiswaitingforit,whileanotheronerefusedto
perform it. Flutter ablation was successful in one of the two
patients while the other one reported atrial tachycardia
episodes after the procedure.
One of the two patients that reported paroxysmal atrial
fibrillation recurrences underwent thyroidectomy to treat
multinodular goiter caused by amiodarone intoxication. The
otherone onlyhad onlyoneepisode <24h at15daysfromthe
surgical procedure that terminated spontaneously. At the
9-month follow-up, both patients that reported paroxysmal
atrial fibrillation recurrences were in sinus rhythm from at
least 6 month and could discontinue antiarrhythmic therapy.
Another patient always reported persistent atrial fibrillation
recurrences in spite of a successful electrical cardioversion.
When patients were grouped according to the type of
atrial fibrillation recorded at the baseline, similar results
were found: at the 12-month follow-up, 67% of patients
with history of paroxysmal atrial fibrillation were free from
atrial arrhythmia recurrences and from antiarrhythmic
drugs, as against 75% of patients with a history of persistent
atrial fibrillation. Anyway our population is too small to
perform a significant comparison.
A previous performed catheter ablation was not predic-
tive a better outcome. All the patients with early arrhythmia
recurrencebeforedischargehadrecurrencesduringfollow-up.
Mean ejection fraction at 6 months follow-up was similar to
the baseline one (61%±11%). No major cardiac complica-
tions, both related and not related to the procedure, were
reported during follow-up.
3.3 Medications
Oral anticoagulation therapy was prescribed on discharge
only to the five patients (23%) who had had atrial
fibrillation episodes during the postoperative period, in-
cluding the only patient with high risk factor (CHADS2
score=3). Owing to atrial arrhythmia recurrence during
follow-up, another three patients restarted oral anticoagula-
tion therapy during the follow-up. A total of seven patients
(32%) were taking oral anticoagulation therapy at the last
follow-up examination.
Antiarrhythmic therapy was completely discontinued in
16 (%) patients at the 12-month follow-up examination, as
0%
82%
91%
70%
86%
91% 90%
70%
73%
0%
77%
91%
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
3 months (N=22) 6 months (N=22) 12 months (N=22) 24 months (N=10)
Pts free from any arrhythmia and from AAD Pts free from any arrhythmia Pts free from AF Fig. 3 Primary endpoint:
percentage of patients free from
any atrial arrhythmia recurrence
and from antiarrhythmic drugs
at difference follow-up.
Secondary endpoints: percentage
of patients free from any atrial
arrhythmia recurrence and
percentage of patients free from
atrial fibrillation recurrence.
AF atrial fibrillation, AAD
antiarrhythmic drugs
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last 6 months of follow-up. The patient that performed
successful flutter ablation is still under antiarrhythmic therapy
since he is in sinus rhythm for only 5 months.
4 Discussion
This paper describes our single-center experience with a
minimally invasive stand-alone surgical ablation technique
that combines pulmonary vein isolation, targeted partial
autonomic denervation, and left atrial appendage exclusion.
This new technique was developed in 2008 by Bauer [11],
and in the last 2 years, many authors have reported good
results in terms of safety and freedom from atrial fibrillation
on medium-term follow-up, after using different devices
and methodologies [8–14]. Owing to the possibility of
creating transmural lesions on the beating heart through
alternative, less invasive incisions, surgical ablation is
gaining ground in patients with atrial fibrillation. It is now
also becoming general practice to treat atrial fibrillation in
patients that are candidates for major surgery, such as mitral
valve replacement/repair or coronary artery bypass graft,
since this arrhythmia is an independent risk factor for
increased postsurgical mortality; very good results have
been reported [17–19].
In our thought minimally invasive stand-alone surgical
ablation should represent the next therapeutic step following
one or more unsuccessful catheter ablations. The benefits of
this procedure are direct visualization using minithoracoto-
mies, absence of fluoroscopy, and possibility to exclude the
left atrial appendage and to address multiple potential
mechanism of atrial fibrillation (ectopic foci, ligament of
Marshall, and autonomic ganglia). Thus with this approach, it
is possible to perform continuous and transmural lesions that
should be more difficult to recover in respect to the
endocardial ones.
Ourdata are noteworthy since they showthe success rate of
this procedure in a population of consecutive patients with
atrial fibrillation, 73% of whom had not responded to previous
multiple catheter pulmonary vein ablations. Since not all these
previous endocardial procedureswere performedin our center,
it is difficult to understand the possible causes of these failures.
We hypothesize that the failure of previous endocardial
approaches was due to conduction recovery in some connec-
tion points between PVs and the atrium.
Our 12-month 73% success rate (defined as freedom
from any atrial arrhythmia recurrence longer than 30 s and
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AF: atrial fibrillation. AFL: atrial flutter. AT: atrial tachycardia. ECV: electrical cardioversion.
FU: follow-up.
Fig. 4 Arrhythmia recurrences and management diagram. AF atrial fibrillation, AFL atrial flutter, AT atrial tachycardia, ECV electrical
cardioversion, FU follow-up
84 J Interv Card Electrophysiol (2012) 34:79–87from antiarrhythmic therapy) is based on strict ECG home
monitoring on a daily basis during the first 4 months
and later on quarterly 24-h Holter monitoring. This was
considered enough in the last years [15], but it has been
demonstrated by many studies that the detection of atrial
fibrillation increases on prolonging the monitoring time
[20]. For this reason, strict ECG monitoring is fundamental
to ensuring that asymptomatic arrhythmia recurrences are
detected. According to the new guidelines [16], a monthly
24-h Holter monitoring or a daily ECG monitoring should
be performed for at least 1 year of follow-up. Currently we
follow these recommendations in implanting a continuous
cardiac monitor in all the patients undergoing this proce-
dure, as performed in the last three patients enrolled in this
cohort.
Although our population included higher proportions of
patients with persistent atrial fibrillation, previous failed
catheter ablations, and daily ECG monitoring, our results
are comparable, in terms of freedom from any atrial
arrhythmia, to those reported in previous studies with even
less strict success definitions [9, 13, 15]. We decided not to
consider the first 3 months as a blanking period because we
have noted that early recurrences are predictive of later
recurrences in the follow-up period, as already reported by
other authors [14].
We found an 18% incidence of new-onset left atrial flutter
in patients that previously performed catheter ablation. This
very high incidence of new-onset atrial flutter could be due to
the fact that no extra lines apart from pulmonary vein
isolations were performed in these patients both during
catheter and surgical ablation. Anyway, due to the fact that
the average timeoffirst atrialflutter recurrenceis8±5 months
following surgical ablation, it is not possible to verify if there
is a direct correlation with the surgical procedure or with the
catheter ablation.
It is important to underline that previously ineffective
antiarrhythmic drugs, even after catheter ablation, started to
control atrial fibrillation after the surgical procedure in the
majority of patients. Probably this is due to the substrate
modification induced by the surgical procedure. The efficacy
of the procedure is maintained even after 2 years of follow-up
without the addictive effect of antiarrhythmic therapy.
Autonomic denervation and ligament of Marshall resec-
tion have been suggested to eliminate the triggering of
pulmonary vein firing from the left atrium, improving the
outcome of the procedure [10, 12, 14]. However, it is not
yet demonstrated whether there is an additive effect of
autonomic ganglia ablation in terms of success rate, in that
discrepant results have emerged from previous studies [14].
Also in our population, it is not possible to draw
conclusion, since these procedures were performed in all
the patients. Atrial appendage exclusion also offers benefits
in terms of stroke prevention, though further studies on this
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J Interv Card Electrophysiol (2012) 34:79–87 85issue are needed in order to ascertain whether it is safe to
discontinue oral anticoagulant therapy in these patients [21].
We think that, in some cases, a hybrid approach (catheter
plus surgical ablation) could yield a higher success rate. In
our population, previous catheter ablation was not predictive
of greater success even if success rate in this subgroup of
patients could be attributed to the combination of the two
treatments. However, this may have been due to the limited
number of patients.
5 Limitations
Our experience is on a limited number of patients with
different types of atrial fibrillation undergoing minimally
invasive surgical ablation of atrial fibrillation. As for previous
studies on this topic, results cannot be extended to other
centers performing the same procedure. Moreover, in the
majority of patients, the intensity of monitoring was higher
during the period of pharmacological support and lower when
antiarrhythmic therapy was stopped, thus introducing a
potential bias in the results. More investigations, including
multicenter randomized studies, are required in order to
determine whether the risk/benefit ratio and the costs of this
new technique are acceptable.
6 Conclusions
Minimally invasive surgical ablation in patients with atrial
fibrillation is a feasible technique and gave satisfactory results
that persist at long-term follow-up. Atrial fibrillation recur-
rence alone is low, while we still have a high incidence of
atrial flutter and tachycardia in the follow-up. It remains to be
proven that atrial flutter recurrences can be managed by
subsequent flutter ablation. Further multicenter studies in-
volving larger populations are needed in order to confirm the
results of single-center experiences and to update atrial
fibrillation guidelines on this procedure.
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